Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million

Bulletin Express07-02 17:25

On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its share structure.

Key developments 1. Conversion of unlisted shares: On 4 June 2026, 44.39 million unlisted domestic shares were converted into H shares, increasing the company’s outstanding H-share count by 28.96% to 197.67 million. The pool of unlisted shares fell to 1.22 million.

2. Authorised share capital enlarged: Total authorised/registered capital rose by the same 44.39 million shares to 198.89 million shares, each with a par value of RMB 1, reflecting the full impact of the conversion.

3. Equity incentive issuance: Within the month’s movements, 9.94 million new H shares were issued under the company’s H Share Award Scheme approved on 17 December 2025; these shares formed part of the overall conversion described above.

4. Public-float compliance affirmed: Leads Biolabs confirmed that, following the share conversion, it continues to meet the Main Board’s minimum 25% public-float requirement.

As at 30 June 2026, Leads Biolabs had no treasury shares and reported total issued share capital of 197.67 million H shares and 1.22 million remaining unlisted shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189242408?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189242408","market":"hk","top_or_hot":-1,"title":"Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million","media":"Bulletin Express","content":"<p>On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its share structure.</p>\n<p>Key developments  \n1. Conversion of unlisted shares: On 4 June 2026, 44.39 million unlisted domestic shares were converted into H shares, increasing the company’s outstanding H-share count by 28.96% to 197.67 million. The pool of unlisted shares fell to 1.22 million.</p>\n<p>2. Authorised share capital enlarged: Total authorised/registered capital rose by the same 44.39 million shares to 198.89 million shares, each with a par value of RMB 1, reflecting the full impact of the conversion.</p>\n<p>3. Equity incentive issuance: Within the month’s movements, 9.94 million new H shares were issued under the company’s H Share Award Scheme approved on 17 December 2025; these shares formed part of the overall conversion described above.</p>\n<p>4. Public-float compliance affirmed: Leads Biolabs confirmed that, following the share conversion, it continues to meet the Main Board’s minimum 25% public-float requirement.</p>\n<p>As at 30 June 2026, Leads Biolabs had no treasury shares and reported total issued share capital of 197.67 million H shares and 1.22 million remaining unlisted shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its share structure.</p>\n<p>Key developments  \n1. Conversion of unlisted shares: On 4 June 2026, 44.39 million unlisted domestic shares were converted into H shares, increasing the company’s outstanding H-share count by 28.96% to 197.67 million. The pool of unlisted shares fell to 1.22 million.</p>\n<p>2. Authorised share capital enlarged: Total authorised/registered capital rose by the same 44.39 million shares to 198.89 million shares, each with a par value of RMB 1, reflecting the full impact of the conversion.</p>\n<p>3. Equity incentive issuance: Within the month’s movements, 9.94 million new H shares were issued under the company’s H Share Award Scheme approved on 17 December 2025; these shares formed part of the overall conversion described above.</p>\n<p>4. Public-float compliance affirmed: Leads Biolabs confirmed that, following the share conversion, it continues to meet the Main Board’s minimum 25% public-float requirement.</p>\n<p>As at 30 June 2026, Leads Biolabs had no treasury shares and reported total issued share capital of 197.67 million H shares and 1.22 million remaining unlisted shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1189242408","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189242408","pubTimestamp":1782984351,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Leads Biolabs将4439万股非上市股份转换为H股，流通H股增至1.9767亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its share structure.\nKey developments  \n1. Conversion of unlisted shares: On 4 June 2026, 44.39 million unlisted domestic shares were converted into H shares, increasing the company’s outstanding H-share count by 28.96% to 197.67 million. The pool of unlisted shares fell to 1.22 million.\n2. Authorised share capital enlarged: Total authorised/registered capital rose by the same 44.39 million shares to 198.89 million shares, each with a par value of RMB 1, reflecting the full impact of the conversion.\n3. Equity incentive issuance: Within the month’s movements, 9.94 million new H shares were issued under the company’s H Share Award Scheme approved on 17 December 2025; these shares formed part of the overall conversion described above.\n4. Public-float compliance affirmed: Leads Biolabs confirmed that, following the share conversion, it continues to meet the Main Board’s minimum 25% public-float requirement.\nAs at 30 June 2026, Leads Biolabs had no treasury shares and reported total issued share capital of 197.67 million H shares and 1.22 million remaining unlisted shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189242408","isCrawlerRequest":true}